Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2024.07.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Izel Okcu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Mediastinal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Mayo Clinic.
Abstract (Originalsprache)
BACKGROUND: Primary mediastinal large B-cell lymphoma (PMBCL) is an uncommon type of aggressive B-cell non-Hodgkin lymphoma. PMBCL shares some clinical and biologic features with nodular sclerosis classic Hodgkin lymphoma (cHL). Central nervous system (CNS) relapse is exceedingly rare in cHL. Therefore, it may be expected that CNS relapse in PMBCL is also uncommon. Herein, we examined the incidence of CNS relapse in patients with PMBCL treated with standard chemoimmunotherapy. PATIENTS AND METHODS: This retrospective single center analysis included 154 patients with newly diagnosed PMBCL seen at Mayo Clinic. The CNS relapse rate was calculated using a competing risk model, with death considered as a competing risk. RESULTS: With a median follow-up of 39 months, 3 patients experienced CNS relapse, all associated with systemic relapse. The cumulative incidence of CNS relapse for the entire cohort was 1.43% (95% CI, 0.3%-4.6%) at 1 year and 2.21% (95% CI, 0.6%-5.8%) at both 2 and 5 years. For those who did not receive CNS prophylaxis (n = 131), the incidence was 0.85% (95% CI, 0.1%-4.2%) at 1 year and 1.80% (95% CI, 0.3%-5.8%) at both 2 and 5 years. All 3 patients who experienced CNS relapse had R-CHOP as frontline therapy; 2 patients did not receive any CNS prophylaxis, while 1 patient received intrathecal CNS prophylaxis. CONCLUSION: The risk of CNS relapse in PMBCL appears to be very low after treatment with standard chemoimmunotherapy, suggesting routine CNS prophylaxis is not necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, MN.
- Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
- Department of Hematology, Shenzhen People's Hospital, Shenzhen, China.
- Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL.
- Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
Förderung
- Mayo Clinic
Zitieren
APA
Okcu, I., Wang, Y., Bock, A. M., Zhou, J., Moustafa, M. A., Tun, H. W., Rosenthal, A. C., Johnston, P. B., Baidoun, F., Khurana, A., Kabat, B. F., King, R. L., Habermann, T. M., & Nowakowski, G. S. (2025). Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.07.019
Vancouver
Okcu I, Wang Y, Bock AM, Zhou J, Moustafa MA, Tun HW, et al. Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2024.07.019
BibTeX
@article{Okcu2025,
author = {Okcu, Izel and Wang, Yucai and Bock, Allison M and Zhou, Jihao and Moustafa, Muhamad Alhaj and Tun, Han W and Rosenthal, Allison C and Johnston, Patrick B and Baidoun, Firas and Khurana, Arushi and Kabat, Brian F and King, Rebecca L and Habermann, Thomas M and Nowakowski, Grzegorz S},
title = {Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2024.07.019}
}
EUVIMED